By Fineline Cube 
China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) announced that its clinical trial application for VUM02, a therapeutic biologic product derived from human umbilical cord mesenchymal stem cells, has been accepted for review by the Center for Drug Evaluation (CDE). The product is being developed for the treatment of severe and critical pneumonia.
Product Profile
VUM02 is an internally developed cryopreserved stem-cell preparation. It is derived from umbilical cord tissue of healthy fetuses and undergoes isolation, screening, and in vitro amplification. Currently, no similar product has been approved for this indication globally, with VUM02 being the most advanced in clinical development.-Fineline Info & Tech